Pursuant to section 106(1) of the Medicines Act 1981,
I, Stephen McKernan, Director-General of Health, acting under delegated authority, hereby declare that:
The medicines listed in the Schedule to this notice are classified as prescription medicines.
Every reference to a medicine in this notice applies whether the medicine is synthetic in origin or is from biological
or mineral sources.
Unless specific reference is made otherwise, every reference applies also to medicines that are:
(a) preparations and admixtures containing any proportion of any substance listed in the notice.
(b) salts and esters of any substance listed in the notice.
(c) preparations or extracts of biological materials listed in the notice.
(d) salts or oxides of elements listed in the notice.
Unless specific reference is made otherwise, every reference to a medicine applies:
(i) if the medicine is in an injection or eye preparation, to any concentration of that medicine; and
(ii) if the medicine is not in an injection or eye preparation, only if the concentration of the medicine is greater than 10 milligrams per litre or per kilogram.
Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using
the free acid, base, alcohol or element unless specifically stated otherwise.
Schedule
Prescription Medicines
Amoxycillin; except when combined with clavulanic acid in a medicine that is supplied from a Community-based Assessment Centre established and operated by a district health board in accordance with a protocol approved
by the National Incident Controller for the Influenza A (H1N1) Pandemic
Cefazolin; except when supplied from a Community-based Assessment Centre established and operated by a district health board in accordance with a protocol approved
by the National Incident Controller for the Influenza A (H1N1) Pandemic
Clavulanic acid; except when combined with amoxycillin in a medicine that is supplied from a Community-based Assessment Centre established and operated by a district health board in accordance with a protocol approved
by the National Incident Controller for the Influenza A (H1N1) Pandemic
Doxycycline; except when supplied from a Community-based Assessment Centre established and operated by a district health board in accordance with a protocol approved by the National Incident Controller for the Influenza A (H1N1) Pandemic
Flucloxacillin; except when supplied from a Community-based Assessment Centre established and operated by
a district health board in accordance with a protocol approved by the National Incident Controller for the Influenza A (H1N1) Pandemic
Oseltamivir; except when sold by a registered pharmacist between the months of May to September inclusive
for the treatment of seasonal influenza to a consumer
12 years of age or more presenting in a pharmacy with early symptoms of influenza; except when supplied from a Community-based Assessment Centre established and operated by a district health board in accordance with
a protocol approved by the National Incident Controller for the Influenza A (H1N1) Pandemic
Sulfamethoxazole; except when combined with trimethoprim in a medicine that is supplied from a Community-based Assessment Centre established and operated by a district health board in accordance with a protocol approved
by the National Incident Controller for the Influenza A (H1N1) Pandemic
Trimethoprim; except when combined with sulfamethoxazole in a medicine that is supplied from a Community-based Assessment Centre established and operated by a district health board in accordance with a protocol approved
by the National Incident Controller for the Influenza A (H1N1) Pandemic
Zanamivir; except when supplied from a Community-based Assessment Centre established and operated by a district health board in accordance with a protocol approved
by the National Incident Controller for the Influenza A (H1N1) Pandemic
Dated this 19th day of June 2009.
STEPHEN MCKERNAN, Director-General of Health.